The optimal duration of treatment with each drug has yet ... data from the phase II CheckMate 142 trial suggested nivolumab plus ipilimumab provided better outcomes than did single-agent nivolumab.

ICI-based combinations are the preferred first-line therapy due to their proven superiority over TKI monotherapy, many patients were not receiving them,” the researchers wrote.

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...

(Jan. 2 issue), 1 the combination of nivolumab and ipilimumab resulted in an unprecedented increase in overall and melanoma-specific survival, as compared with ipilimumab alone. We should be wary ...

The committee based its decision on data showing the subcutaneous formulation of Opdivo was not inferior to the intravenous formulation.

The researchers called for further study to understand the mechanism of the relationship between obesity and ICI outcomes.

Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.

Princeton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

monotherapy maintenance following completion of nivolumab plus Yervoy (ipilimumab)combination therapy, or in combination with chemotherapy or cabozantinib. The CHMP opinion will now be reviewed by ...